Breaking News

Molecular Profiles Opens Nottingham Site

July 12, 2013

Completes successful MHRA inspection

Molecular Profiles has opened its new facility in Nottingham following a successful MHRA inspection. The £9 million, 30,000-sq.-ft. pharmaceutical production facility will provide clinical manufacturing capabilities designed to handle a range of non-sterile dosage forms such as solids, liquids, semi-solids and inhaled products. The investment adds six GMP suites, new labs, and a dedicated clinical packing area to support Phase I and II clinical trials. The facility also allows for the manufacture of highly potent compounds up to OEB 4 level with manufacturing batch scale of up to 30kg.
 
Nikin Patel, chief executive officer of Molecular Profiles, said, “Receiving our license from the MHRA for our new site is probably the biggest milestone for our business since we set-up shop so is naturally a very exciting time for everyone involved. From a commercial perspective, we are very much open for business and have already received significant interest from companies looking to use our manufacturing capabilities to assist with their clinical trial requirements."
 
The company's new vice president Steve Kemp added, “We have enjoyed a sustained and gradual period of growth over the last decade driven by our consulting, formulation development and analytical services but we are expecting our expanded manufacturing facilities to take us to the next level by helping us better compete on a global scale.”
 
  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems